Please assess the completion status of the following clinical trial:

Trial Title: Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA~* Males and Females ≥ 18 years old diagnosed with HER2 positive breast cancer~* Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy. Pertuzumab may be used in conjunction with trastuzumab.~* Left Ventricular Ejection Fraction (LVEF) ≥ 50% by MUGA scan or echocardiogram~* Adequate renal function for administration of trastuzumab-containing chemotherapy regimen.~* Sitting systolic blood pressure of \> 90 mm Hg~* Pulse ≥ 60 beats/minute~* Not pregnant or breastfeeding~* Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study~* Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents~* Able to swallow capsules~EXCLUSION CRITERIA:~* Patients with metastatic disease~* Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen~* Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, β-blockers or digoxin~* Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction~* Known allergy to either ACE inhibitors or β-blockers~* History of bronchial asthma or related bronchospastic conditions~* Hereditary or idiopathic angioedema~* History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings~* This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I lisinopril (Type: EXPERIMENTAL): Patients receive oral lisinopril once daily.
- Arm II Coreg CR® (Type: EXPERIMENTAL): Patients receive oral Coreg CR® once daily.
- Arm III placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).